Serum Lipase

When elevated (>60 U/L):

Immediate actions:

• Determine the cause: GLP-1 therapy, GH/insulin use, oral AAS, alcohol, or hypertriglyceridemia
• If on GLP-1 agonists: mild to moderate elevation (1-3x ULN) without symptoms is expected pharmacological effect, not pancreatitis. Compare to your baseline.
• Check amylase alongside lipase for cross-reference
• Check triglycerides: levels above 11.3 mmol/L can independently cause pancreatitis

If mildly elevated (60-180 U/L, 1-3x ULN) without symptoms:

• On GLP-1 therapy: This is the expected range. The LEADER trial showed lipase increases of 28-31% are normal. Document the reading and recheck at next scheduled bloodwork. No dose adjustment needed.
• On GH/insulin: Consider reducing GH dose or cycling off for 2-4 weeks, then recheck
• On oral AAS: Discontinue hepatotoxic orals (Dianabol, Winstrol, Superdrol). Recheck in 2-4 weeks.
• Eliminate alcohol completely during any protocol that stresses the pancreas
• NAC 600mg 2x/day and TUDCA 250-500mg/day for hepatobiliary support

If significantly elevated (>180 U/L, >3x ULN):

• Even without symptoms, 3x ULN warrants closer monitoring. Recheck in 1-2 weeks.
• If on GLP-1: up to 8.3% of users exceed 3x ULN without pancreatitis. The positive predictive value for actual pancreatitis at this threshold is less than 1%.
• If accompanied by severe abdominal pain (especially radiating to the back), nausea, and vomiting: seek medical attention immediately. Stop all PEDs and GLP-1 therapy pending evaluation.
• Imaging (abdominal CT or ultrasound) is warranted if symptoms are present

When low (<10 U/L):

• Rarely clinically significant in isolation
• Extremely low levels may suggest chronic pancreatic insufficiency or cystic fibrosis
• If accompanied by steatorrhea (fatty stools), malabsorption, or unintended weight loss, further pancreatic function testing is warranted

Prevention:

• Get baseline lipase before starting GLP-1 agonists, GH, insulin, or oral AAS protocols
• Recheck at 4-6 weeks after starting or dose-escalating GLP-1 therapy
• Keep triglycerides below 2.3 mmol/L: hypertriglyceridemia is the most modifiable pancreatitis risk factor
• Limit oral AAS cycles to 4-6 weeks maximum
• Avoid alcohol during all hepatotoxic compound cycles
• Lose weight gradually on GLP-1 (target <1 kg/week) to reduce gallstone risk. GLP-1 agonists increase gallbladder disease risk by 37%, and gallstones cause roughly 30% of pancreatitis cases.

References:

• Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., et al. (2017). Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: Results from the LEADER randomized trial. Diabetes Care, 40(7), 966-972. DOI: 10.2337/dc16-2284
• Forsmark, C. E., Vege, S. S., & Wilcox, C. M. (2016). Acute pancreatitis. New England Journal of Medicine, 375(20), 1972-1981. DOI: 10.1056/NEJMra1505202
• He, L., Wang, J., Ping, F., et al. (2022). Association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases. JAMA Internal Medicine, 182(5), 513-519. DOI: 10.1001/jamainternmed.2022.0338